… Our study retrospectively enrolled patients who had received gefitinib, erlotinib or afatinib
for first-line treatment of stage IV or post-operative recurrent (advanced) NSCLC between 2014/…

… , therefore we await the results of other randomized studies with patients treated with the
combination of erlotinib plus bevacizumab in countries other than Japan. Secondly, the …

… of bevacizumab to erlotinib as first-line therapy in … ERLotinib studY (BEVERLY), with the
aim to test whether the addition of bevacizumab to first-line erlotinib prolonged PFS of patients …

… rather than chemotherapy [6], we found that the sequential combination of first-line erlotinib
and second-line chemotherapy conferred comparable survival benefits with the same …

… Erlotinib is indicated as first-line treatment for patients with non-small-cell lung cancer (NSCLC)
harboring an epidermal growth-factor–receptor (EGFR) mutation. Addition of a vascular …

… erlotinib would be safe and show efficacy in patients with EGFR-mutated tumors experiencing
disease progression on erlotinib … patients with EGFR WT tumors with MET dysregulation. …

… In the United States, erlotinib is approved for the first or subsequent line treatment of EGFR
mutation-positive (exon 19 deletions or L858R mutations) patients with metastatic NSCLC; …

… Full-text articles written in English were captured if they provided an original economic
evaluation of erlotinib in first-line treatment of NSCLC patients. Clinical trials, review papers, …

… -line EGFR-TKI therapy (ie gefitinib, erlotinib or afatinib) by the time of enrollment in the study.
Patients … or second-line chemotherapy [CT]) prior to first- or second-generation EGFR-TKIs. …

… with the following TKI treatment; 40 treated with afatinib, 33 with gefitinib, and 26 with erlotinib.
Median PFS was not significantly different between treatment groups; 15.4 months (95% …